242 related articles for article (PubMed ID: 18371182)
1. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402.
Giannini C; Burger PC; Berkey BA; Cairncross JG; Jenkins RB; Mehta M; Curran WJ; Aldape K
Brain Pathol; 2008 Jul; 18(3):360-9. PubMed ID: 18371182
[TBL] [Abstract][Full Text] [Related]
2. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
; Cairncross G; Berkey B; Shaw E; Jenkins R; Scheithauer B; Brachman D; Buckner J; Fink K; Souhami L; Laperierre N; Mehta M; Curran W
J Clin Oncol; 2006 Jun; 24(18):2707-14. PubMed ID: 16782910
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
Cairncross G; Wang M; Shaw E; Jenkins R; Brachman D; Buckner J; Fink K; Souhami L; Laperriere N; Curran W; Mehta M
J Clin Oncol; 2013 Jan; 31(3):337-43. PubMed ID: 23071247
[TBL] [Abstract][Full Text] [Related]
4. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
van den Bent MJ; Dubbink HJ; Marie Y; Brandes AA; Taphoorn MJ; Wesseling P; Frenay M; Tijssen CC; Lacombe D; Idbaih A; van Marion R; Kros JM; Dinjens WN; Gorlia T; Sanson M
Clin Cancer Res; 2010 Mar; 16(5):1597-604. PubMed ID: 20160062
[TBL] [Abstract][Full Text] [Related]
5. Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma.
Polivka J; Polivka J; Repik T; Rohan V; Hes O; Topolcan O
Anticancer Res; 2016 Jan; 36(1):471-6. PubMed ID: 26722084
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
van den Bent MJ; Brandes AA; Taphoorn MJ; Kros JM; Kouwenhoven MC; Delattre JY; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Enting RH; French PJ; Dinjens WN; Vecht CJ; Allgeier A; Lacombe D; Gorlia T; Hoang-Xuan K
J Clin Oncol; 2013 Jan; 31(3):344-50. PubMed ID: 23071237
[TBL] [Abstract][Full Text] [Related]
7. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade.
Iwadate Y; Matsutani T; Hara A; Hirono S; Ikegami S; Kobayashi M; Ito D; Kawauchi D; Horiguchi K; Tamiya A; Higuchi Y
J Neurooncol; 2019 Jan; 141(1):205-211. PubMed ID: 30565028
[TBL] [Abstract][Full Text] [Related]
8. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies.
Roth P; Wick W; Weller M
Curr Treat Options Oncol; 2013 Dec; 14(4):505-13. PubMed ID: 23907441
[TBL] [Abstract][Full Text] [Related]
9. Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors.
Chen H; Thomas C; Munoz FA; Alexandrescu S; Horbinski CM; Olar A; McGuone D; Camelo-Piragua S; Wang L; Pentsova E; Phillips J; Aldape K; Chen W; Iafrate AJ; Chi AS; Zagzag D; Golfinos JG; Placantonakis DG; Rosenblum M; Ohman-Strickland P; Hameed M; Snuderl M
Neuro Oncol; 2019 Sep; 21(9):1164-1174. PubMed ID: 31140557
[TBL] [Abstract][Full Text] [Related]
10. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.
Frenel JS; Leux C; Loussouarn D; Le Loupp AG; Leclair F; Aumont M; Mervoyer A; Martin S; Denis MG; Campone M
J Neurooncol; 2013 Aug; 114(1):85-91. PubMed ID: 23681562
[TBL] [Abstract][Full Text] [Related]
11. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.
Jiang H; Ren X; Cui X; Wang J; Jia W; Zhou Z; Lin S
Neuro Oncol; 2013 Jun; 15(6):775-82. PubMed ID: 23486687
[TBL] [Abstract][Full Text] [Related]
12. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic oligodendroglial tumors harboring 1p/19q deletion can be successfully treated without radiotherapy.
Iwadate Y; Matsutani T; Shinozaki N; Saeki N
Anticancer Res; 2011 Dec; 31(12):4475-9. PubMed ID: 22199318
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
Kouwenhoven MC; Gorlia T; Kros JM; Ibdaih A; Brandes AA; Bromberg JE; Mokhtari K; van Duinen SG; Teepen JL; Wesseling P; Vandenbos F; Grisold W; Sipos L; Mirimanoff R; Vecht CJ; Allgeier A; Lacombe D; van den Bent MJ
Neuro Oncol; 2009 Dec; 11(6):737-46. PubMed ID: 19224764
[TBL] [Abstract][Full Text] [Related]
15. Regional specificity of 1p/19q co-deletion combined with radiological features for predicting the survival outcomes of anaplastic oligodendroglial tumor patients.
Wang K; Wang Y; Fan X; Li Y; Liu X; Wang J; Ai L; Dai J; Jiang T
J Neurooncol; 2018 Feb; 136(3):523-531. PubMed ID: 29230668
[TBL] [Abstract][Full Text] [Related]
16. Tumor cell-specific chromosomal abnormality in the vascular endothelial cells of anaplastic oligodendroglioma.
Jiang H; Zhang Z; Ren X; Zeng W; Wang J; Lin S
J Neurosurg; 2016 Oct; 125(4):995-1001. PubMed ID: 26771849
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
van den Bent MJ; Carpentier AF; Brandes AA; Sanson M; Taphoorn MJ; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Haaxma-Reiche H; Kros JM; van Kouwenhoven MC; Vecht CJ; Allgeier A; Lacombe D; Gorlia T
J Clin Oncol; 2006 Jun; 24(18):2715-22. PubMed ID: 16782911
[TBL] [Abstract][Full Text] [Related]
18. Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment?
Ramirez C; Bowman C; Maurage CA; Dubois F; Blond S; Porchet N; Escande F
Neuro Oncol; 2010 May; 12(5):490-9. PubMed ID: 20156805
[TBL] [Abstract][Full Text] [Related]
19. Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy.
Iwadate Y; Matsutani T; Hasegawa Y; Shinozaki N; Higuchi Y; Saeki N
J Neurooncol; 2011 May; 102(3):443-9. PubMed ID: 20721680
[TBL] [Abstract][Full Text] [Related]
20. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival.
Felsberg J; Erkwoh A; Sabel MC; Kirsch L; Fimmers R; Blaschke B; Schlegel U; Schramm J; Wiestler OD; Reifenberger G
Brain Pathol; 2004 Apr; 14(2):121-30. PubMed ID: 15193024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
